Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell vaccine (Baylor Research Institute)
- Development stage
- Unknown
- Lead developer
- Baylor Research Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intratumoral, Subcutaneous
01
Overview
This autologous dendritic cell vaccine is an investigational immunotherapy developed by the Baylor Research Institute for the treatment of breast cancer, including triple-negative (TNBC) and ER+/HER2- subtypes. The vaccine is produced by collecting a patient's monocytes via apheresis, differentiating them into dendritic cells ex vivo, and loading them with specific tumor-associated antigens, including Cyclin B1 and Wilms Tumor 1 (WT1). The vaccine is administered both intratumorally and subcutaneously to stimulate the patient's immune system, specifically aiming to activate CD8+ cytotoxic T cells to recognize and destroy breast cancer cells. It has been evaluated in a pilot safety trial in combination with preoperative chemotherapy for locally advanced disease.
- Other names
- Cyclin B1/WT-1/CEF-loaded DC vaccineautologous dendritic cell vaccine (Baylor Research Institute)
02
Targets
WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on dendritic cell vaccine (Baylor Research Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell vaccine (Baylor Research Institute).